Vertex's CRISPR-edited cell therapy for sickle cell disease and beta-thalassemia turned gene editing into an approved product, and the 2025 patent record shows the IP catching up. US12497614B2 - "Compositions and methods for editing beta-globin for treatment of hemaglobinopathies," issued December 16, 2025 to Vertex Pharmaceuticals Incorporated - and its companion US12492388B2 claim that editing strategy.
The defining limitations are the target and the edit. These are not platform-architecture claims; they tie CRISPR editing specifically to the beta-globin locus and the goal of treating hemoglobinopathies. The CPC tags - C12N 15/113 (the editing-relevant nucleic acids), C12N 9/22 (Cas), A61P 7/06 (treating anemias), with cell-engineering tags (C12N 5/0647, C12N 5/0696) - describe an ex-vivo cell-editing therapeutic.
Why does the target-gene limitation anchor the claim? Because the foundational editing machinery is owned upstream; what Vertex can own at the product level is the specific application - editing this locus, to achieve this clinical effect, in these cells. The claim's enforceable scope is the editing strategy for hemoglobinopathy, not CRISPR in the abstract.
The companion grant {link('US12492388B2')} ('Materials and methods for treatment of hemoglobinopathies') shows the layering: a product position is rarely one patent but a family of claims around the target, the edit, the cell process, and the therapeutic use. Reading any one in isolation understates the protection; the family is the moat.
For the landscape, these grants are the IP correlate of gene editing's first commercial success. They demonstrate the now-standard structure: foundational architecture held upstream (Broad, Harvard), and disease-and-target product claims held by the commercializing developer. Freedom-to-operate for a competing hemoglobinopathy editing therapy means clearing both layers - the machinery and the target-specific product claims like these.